Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer

Background In many trials (including E2100), bevacizumab (Bmab) monotherapy has been continued if toxicity of paclitaxel (PTX) becomes unacceptable during combined treatment with Bmab and PTX. When progression occurs on Bmab monotherapy, one possible option is re-induction with the combination of Bm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer (Tokyo, Japan) Japan), 2017, Vol.24 (1), p.147-151
Hauptverfasser:	Yoshinami, Tetsuhiro, Yagi, Toshinari, Okuno, Jun, Kittaka, Nobuyoshi, Ishitobi, Makoto, Sugimoto, Naotoshi, Nakayama, Takahiro, Tamaki, Yasuhiro, Imamura, Fumio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Bevacizumab - adverse effects Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer Research Care and treatment Fatigue - chemically induced Female Humans Induction Chemotherapy - methods Medical research Medicine Medicine & Public Health Medicine, Experimental Metastasis Middle Aged Neutropenia - chemically induced Oncology Original Article Paclitaxel - administration & dosage Paclitaxel - adverse effects Retrospective Studies Surgery Surgical Oncology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!